When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
The company to receive upfront and milestone payments, in addition to royalties
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Domestic business was up 41.9% YoY and 27.7% QoQ
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Subscribe To Our Newsletter & Stay Updated
